ADAM17 and neoplasm: Therefore, we hypothesize that increased ADAM17 released into the bloodstream is rather a surrogate for tumor progression in early-stage disease than a surrogate for increased tumor burden of advanced disease, pointing to the complex regulation of ADAM17.